Completed PHASE1 INTERVENTIONAL 3-arm NCT03211403

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Male Subjects With High Serum Uric Acid Level

Sponsor: Atridia Pty Ltd.

Conditions Gout Hyperuricemia

Interventions SHR4640

Updated 7 times since 2017 Last updated: Mar 20, 2018 Started: Jul 4, 2017 Primary completion: Feb 15, 2018 Completion: Feb 15, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03211403, this PHASE1 trial focuses on Gout and Hyperuricemia and remains completed. Sponsored by Atridia Pty Ltd., it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Apr 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Nov 2017 — Apr 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2017 — Nov 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atridia Pty Ltd.

Data source: Atridia Pty Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia